Yaky Yanay
2011
In 2011, Yaky Yanay earned a total compensation of $861.9K as Chief Financial Officer at Pluristem Therapeutics, a 198% increase compared to previous year.
Compensation breakdown
| Salary | $200,760 |
|---|---|
| Stock Awards | $629,400 |
| Other | $31,742 |
| Total | $861,902 |
Yanay received $629.4K in stock awards, accounting for 73% of the total pay in 2011.
Yanay also received $200.8K in salary and $31.7K in other compensation.
Rankings
In 2011, Yaky Yanay's compensation ranked 6,190th out of 10,747 executives tracked by ExecPay. In other words, Yanay earned more than 42.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,190 out of 10,747 | 42nd |
Division Manufacturing | 2,244 out of 3,960 | 43rd |
Major group Chemicals And Allied Products | 508 out of 1,033 | 51st |
Industry group Drugs | 333 out of 781 | 57th |
Industry Biological Products, Except Diagnostic Substances | 50 out of 157 | 68th |
Source: SEC filing on March 22, 2012.
Yanay's colleagues
We found one more compensation record of an executive who worked with Yaky Yanay at Pluristem Therapeutics in 2011.
2011
Zami Aberman
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019